182 related articles for article (PubMed ID: 34215617)
1. Loss-of-Function Mutations in TRAF7 and KLF4 Cooperatively Activate RAS-Like GTPase Signaling and Promote Meningioma Development.
Najm P; Zhao P; Steklov M; Sewduth RN; Baietti MF; Pandolfi S; Criem N; Lechat B; Maia TM; Van Haver D; Corthout N; Eyckerman S; Impens F; Sablina AA
Cancer Res; 2021 Aug; 81(16):4218-4229. PubMed ID: 34215617
[TBL] [Abstract][Full Text] [Related]
2. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
Reuss DE; Piro RM; Jones DT; Simon M; Ketter R; Kool M; Becker A; Sahm F; Pusch S; Meyer J; Hagenlocher C; Schweizer L; Capper D; Kickingereder P; Mucha J; Koelsche C; Jäger N; Santarius T; Tarpey PS; Stephens PJ; Andrew Futreal P; Wellenreuther R; Kraus J; Lenartz D; Herold-Mende C; Hartmann C; Mawrin C; Giese N; Eils R; Collins VP; König R; Wiestler OD; Pfister SM; von Deimling A
Acta Neuropathol; 2013 Mar; 125(3):351-8. PubMed ID: 23404370
[TBL] [Abstract][Full Text] [Related]
3. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Clark VE; Erson-Omay EZ; Serin A; Yin J; Cotney J; Ozduman K; Avşar T; Li J; Murray PB; Henegariu O; Yilmaz S; Günel JM; Carrión-Grant G; Yilmaz B; Grady C; Tanrikulu B; Bakircioğlu M; Kaymakçalan H; Caglayan AO; Sencar L; Ceyhun E; Atik AF; Bayri Y; Bai H; Kolb LE; Hebert RM; Omay SB; Mishra-Gorur K; Choi M; Overton JD; Holland EC; Mane S; State MW; Bilgüvar K; Baehring JM; Gutin PH; Piepmeier JM; Vortmeyer A; Brennan CW; Pamir MN; Kiliç T; Lifton RP; Noonan JP; Yasuno K; Günel M
Science; 2013 Mar; 339(6123):1077-80. PubMed ID: 23348505
[TBL] [Abstract][Full Text] [Related]
4. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
[TBL] [Abstract][Full Text] [Related]
5. TRAF7 enhances ubiquitin-degradation of KLF4 to promote hepatocellular carcinoma progression.
He H; Wu Z; Li S; Chen K; Wang D; Zou H; Chen H; Li Y; Liu Z; Qu C
Cancer Lett; 2020 Jan; 469():380-389. PubMed ID: 31730901
[TBL] [Abstract][Full Text] [Related]
6. Genetic landscape of meningioma.
Yuzawa S; Nishihara H; Tanaka S
Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
[TBL] [Abstract][Full Text] [Related]
7. KLF4
von Spreckelsen N; Waldt N; Poetschke R; Kesseler C; Dohmen H; Jiao HK; Nemeth A; Schob S; Scherlach C; Sandalcioglu IE; Deckert M; Angenstein F; Krischek B; Stavrinou P; Timmer M; Remke M; Kirches E; Goldbrunner R; Chiocca EA; Huettelmaier S; Acker T; Mawrin C
Acta Neuropathol Commun; 2020 Apr; 8(1):41. PubMed ID: 32245394
[TBL] [Abstract][Full Text] [Related]
8. Single-cell DNA sequencing reveals order of mutational acquisition in TRAF7/AKT1 and TRAF7/KLF4 mutant meningiomas.
Dogan H; Blume C; Patel A; Jungwirth G; Sogerer L; Ratliff M; Ketter R; Herold-Mende C; Jones DTW; Wick W; Vollmuth P; Zweckberger K; Reuss D; von Deimling A; Sahm F
Acta Neuropathol; 2022 Oct; 144(4):799-802. PubMed ID: 35984495
[No Abstract] [Full Text] [Related]
9. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.
Jungwirth G; Warta R; Beynon C; Sahm F; von Deimling A; Unterberg A; Herold-Mende C; Jungk C
Acta Neuropathol Commun; 2019 Aug; 7(1):140. PubMed ID: 31470906
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system.
Yuzawa S; Nishihara H; Yamaguchi S; Mohri H; Wang L; Kimura T; Tsuda M; Tanino M; Kobayashi H; Terasaka S; Houkin K; Sato N; Tanaka S
Mod Pathol; 2016 Jul; 29(7):708-16. PubMed ID: 27102344
[TBL] [Abstract][Full Text] [Related]
11. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics and Magnetic Resonance Imaging-Based Prediction of the KLF4
von Spreckelsen N; Waldt N; Timmer M; Goertz L; Reinecke D; Laukamp K; Pennig L; Grau S; Deckert M; Kirches E; Stavrinou P; Mawrin C; Goldbrunner R
World Neurosurg; 2021 Oct; 154():e665-e670. PubMed ID: 34343686
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic role of TRAF7 in skull-base meningiomas and congenital heart disease.
Mishra-Gorur K; Barak T; Kaulen LD; Henegariu O; Jin SC; Aguilera SM; Yalbir E; Goles G; Nishimura S; Miyagishima D; Djenoune L; Altinok S; Rai DK; Viviano S; Prendergast A; Zerillo C; Ozcan K; Baran B; Sencar L; Goc N; Yarman Y; Ercan-Sencicek AG; Bilguvar K; Lifton RP; Moliterno J; Louvi A; Yuan S; Deniz E; Brueckner M; Gunel M
Proc Natl Acad Sci U S A; 2023 Apr; 120(16):e2214997120. PubMed ID: 37043537
[TBL] [Abstract][Full Text] [Related]
14. Meningioma: current updates on genetics, classification, and mouse modeling.
Szulzewsky F; Thirimanne HN; Holland EC
Ups J Med Sci; 2024; 129():. PubMed ID: 38571886
[TBL] [Abstract][Full Text] [Related]
15. A new amplicon-based gene panel for next generation sequencing characterization of meningiomas.
Mawrin C; Koch R; Waldt N; Sandalcioglu IE; Braunsdorf WEK; Warnke JP; Goehre F; Meisel HJ; Ewald C; Neyazi S; Schüller U; Kirches E
Brain Pathol; 2022 Mar; 32(2):e13046. PubMed ID: 35213080
[TBL] [Abstract][Full Text] [Related]
16. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas.
Clark VE; Harmancı AS; Bai H; Youngblood MW; Lee TI; Baranoski JF; Ercan-Sencicek AG; Abraham BJ; Weintraub AS; Hnisz D; Simon M; Krischek B; Erson-Omay EZ; Henegariu O; Carrión-Grant G; Mishra-Gorur K; Durán D; Goldmann JE; Schramm J; Goldbrunner R; Piepmeier JM; Vortmeyer AO; Günel JM; Bilgüvar K; Yasuno K; Young RA; Günel M
Nat Genet; 2016 Oct; 48(10):1253-9. PubMed ID: 27548314
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
[TBL] [Abstract][Full Text] [Related]
18. KLF4 is a tumor suppressor in anaplastic meningioma stem-like cells and human meningiomas.
Tang H; Zhu H; Wang X; Hua L; Li J; Xie Q; Chen X; Zhang T; Gong Y
J Mol Cell Biol; 2017 Aug; 9(4):315-324. PubMed ID: 28651379
[TBL] [Abstract][Full Text] [Related]
19. Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas.
Peyre M; Feuvret L; Sanson M; Navarro S; Boch AL; Loiseau H; Kalamarides M
J Neurooncol; 2017 Jul; 133(3):633-639. PubMed ID: 28536991
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of genetic alterations and methylation classes in meningioma.
Berghoff AS; Hielscher T; Ricken G; Furtner J; Schrimpf D; Widhalm G; Rajky U; Marosi C; Hainfellner JA; von Deimling A; Sahm F; Preusser M
Brain Pathol; 2022 Mar; 32(2):e12970. PubMed ID: 35213082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
